Abbisko Cayman shares jump 7.9% on positive clinical trial results
Shares of Abbisko Cayman jump 7.9% to HK$8.95, their biggest one-day percentage gain since June 29, after the company announced positive preliminary efficacy results from a Phase II clinical trial of its achondroplasia drug. The stock hit HK$8.95, its highest level since September 9.
Abbisko Cayman shares rose 7.9% to HK$8.95, putting the stock on course for its biggest one-day percentage gain since June 29. The shares touched their highest level since September 9. The Chinese oncology therapies developer said its unit Abbisko Therapeutics had reported positive preliminary efficacy results from a phase II clinical trial of lavengratinib (ABSK061) for treatment of achondroplasia in children. Year to date, the stock is down 31.7%, while the Hang Seng Biotech Index is up 15.9%.